---
title: Improve walking stability with exercise
nct_id: NCT07618728
phase: NA
status: RECRUITING
sponsor: Universidad Rey Juan Carlos
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07618728"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07618728"
last_fetched: "2026-06-02T14:00:50.922Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking stability with exercise

**Goal (in five words):** Improve walking stability with exercise

**Official Title:** Feasibility and Preliminary Effectiveness of an Individualized Multimodal Group-Based Exercise Programme for People With Parkinson's Disease: A Non-Randomized Feasibility Study

**Trial ID:** [NCT07618728](https://clinicaltrials.gov/study/NCT07618728)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Universidad Rey Juan Carlos
- **Target Enrollment:** 64 participants
- **Start Date:** 2025-09-08
- **Completion Date:** 2026-06
- **Conditions:** PARKINSON DISEASE (Disorder)
- **Interventions:** Exercise Group
- **Intervention Types:** OTHER

## Summary For Families

A team is testing whether a tailored, multimodal group exercise program can be safely delivered and help improve balance, strength, walking and daily function in people with early to mid-stage Parkinson's. Participants do small, supervised group classes with individualized strength, aerobic, balance and flexibility exercises, designed to boost muscle power, endurance and motor control and to complement medications like levodopa rather than replace them. Adults 18 and older with idiopathic Parkinson's at Hoehn and Yahr stages 1 to 3 who can follow instructions are eligible, while people with other neurological or serious medical conditions, significant cognitive impairment (MoCA < 21), recent hospitalization or recent structured exercise are excluded. About 64 people will enroll, with control participants matched to the exercise group by age, sex and disease stage in a sequential recruitment plan to check feasibility and early benefits.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Eligibility Criteria The eligibility criteria will be identical for both the experimental and control groups. However, this study will employ a sequential recruitment design. Participants for the control group will be recruited following the experimental group and will be matched (1:1 ratio) based on sex, age (± 5 years), and disease severity according to the Hoehn \& Yahr (H\&Y) scale.

Inclusion Criteria:

* Subjects diagnosed with Idiopathic Parkinson's Disease according to the UK Parkinson's Disease Society Brain Bank Diagnostic Criteria.
* Subjects staged between 1 and 3 on the Hoehn \& Yahr Scale. For matching purposes, stage 1 includes stage 1.5, and stage 2 includes stage 2.5.

Exclusion Criteria:

* Subjects diagnosed with a neurological disease other than PD.
* Those diagnosed with a cardiovascular, respiratory, or metabolic disease or other conditions that represent a contraindication to physical exercise.
* Those who have suffered an exacerbation or hospitalization in the last three months prior to starting the assessment protocol or during the therapeutic intervention process.
* Those who have received a course of steroids, intravenously or orally, six months prior to the start of the study or during the therapeutic intervention process.
* Those with cognitive impairment (defined as a score \< 21 on the Montreal Cognitive Assessment, MoCA) or language impairments that prevent adequate communication, comprehension, or following of exercise instructions.
* Participation in a structured, individualized strength and/or aerobic exercise program within the three months prior to enrollment.
```

## Locations (1)

- Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain _(40.3458, -3.8249)_

## Central Contacts

- Mario González Iglesias, MSc PhD Student, Physiotherapy — (CONTACT) — +34 622113365 — mario.gonzalez@urjc.es
- Yeray González Zamorano, PhD, Physiotherapy — (CONTACT) — +34 689105357 — yeray.gonzalez@urjc.es

---

*Canonical: https://parkinsonspathways.com/trial/NCT07618728*  
*HTML version: https://parkinsonspathways.com/trial/NCT07618728*  
*Source data: https://clinicaltrials.gov/study/NCT07618728*